Literature DB >> 16404598

Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors.

You-Jung Yang1, Jin-Sook Ryu, Seog-Young Kim, Seung Jun Oh, Ki Chun Im, Heuiran Lee, Sang-Wook Lee, Kyung Ja Cho, Gi-Jeong Cheon, Dae Hyuk Moon.   

Abstract

PURPOSE: 3'-Deoxy-3'-[(18)F]fluorothymidine (FLT) is a promising new radiopharmaceutical for imaging cell proliferation. We evaluated whether FLT PET can be used to monitor early responses to radiation treatment.
METHODS: C3H/HeN mice bearing murine squamous cell carcinomas were randomized to irradiation with 0, 10, or 20 Gy. Twenty-four hours later, the mice were sacrificed for histopathological and biological assessment such as cell cycle analysis, Hoechst staining, and clonogenic cell survival assay. PET scans were performed on other mice after injection of [(18)F]FLT or [(18)F]fluorodeoxyglucose (FDG) before and after radiation treatment, and tumor growth was assessed over 9 days.
RESULTS: Histopathological examination detected no morphological changes 24 h after radiation treatment, but cell cycle analysis showed that irradiated tumors had a decreased fraction of cells in S phase and an increased fraction in G2-M phase, compared with nonirradiated tumors. Irradiated tumors also had a higher incidence of apoptotic features and reduced clonogenic cell survival. Tumor growth was significantly delayed in irradiated mice (p<0.001) compared with control mice. PET images showed increased tumoral uptake of both FLT and FDG before radiation treatment. Following irradiation, FLT uptake differed significantly (p=0.020) from that in control mice. In contrast, FDG uptake after irradiation did not differ significantly from that in control mice.
CONCLUSION: Our finding that tumor uptake of FLT was reduced at 24 h after radiation treatment suggests that FLT PET may be a promising imaging modality for monitoring the early effects of radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16404598     DOI: 10.1007/s00259-005-0011-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  41 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

3.  Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction.

Authors:  Y Saito; C G Milross; W N Hittelman; D Li; T Jibu; L J Peters; L Milas
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-06-01       Impact factor: 7.038

4.  Use of PET to monitor the response of lung cancer to radiation treatment.

Authors:  Y E Erdi; H Macapinlac; K E Rosenzweig; J L Humm; S M Larson; A K Erdi; E D Yorke
Journal:  Eur J Nucl Med       Date:  2000-07

Review 5.  [Current data and perspectives on positron emission tomography oncology-radiotherapy].

Authors:  M Lonneux; M Sibomana; S Pauwels; V Grégoire
Journal:  Cancer Radiother       Date:  1999 Jul-Aug       Impact factor: 1.018

Review 6.  Monitoring response to treatment in patients utilizing PET.

Authors:  Norbert E Avril; Wolfgang A Weber
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

7.  Increased activity of thymidine kinase isozyme in human colon tumor.

Authors:  S Sakamoto; T Iwama; K Tsukada; J Utsunomiya; T Kawasaki; R Okamoto
Journal:  Carcinogenesis       Date:  1984-02       Impact factor: 4.944

8.  Human thymidine kinase 1. Regulation in normal and malignant cells.

Authors:  B Munch-Petersen; L Cloos; H K Jensen; G Tyrsted
Journal:  Adv Enzyme Regul       Date:  1995

9.  Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake.

Authors:  Jeffrey L Schwartz; Yasuko Tamura; Robert Jordan; John R Grierson; Kenneth A Krohn
Journal:  Nucl Med Biol       Date:  2004-05       Impact factor: 2.408

10.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Rainer Kehlbach; Gabi Bartusek; Maren Pritzkow; Mario Sarbia; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-06       Impact factor: 9.236

View more
  28 in total

Review 1.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 2.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 3.  Molecular imaging in clinical trials.

Authors:  Debra Josephs; James Spicer; Michael O'Doherty
Journal:  Target Oncol       Date:  2009-09-21       Impact factor: 4.493

4.  Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.

Authors:  Seung Jin Lee; Hye Young Kang; Seog Young Kim; Jin Hwa Chung; Seung Jun Oh; Jin-Sook Ryu; Sung-Bae Kim; Jong Soon Kang; Song-Kyu Park; Hwan Mook Kim; Myung-Hwa Kim; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

5.  Effectiveness of PET/CT with (18)F-fluorothymidine in the staging of patients with squamous cell head and neck carcinomas before radiotherapy.

Authors:  Radovan Vojtíšek; Jiří Ferda; Jindřich Fínek
Journal:  Rep Pract Oncol Radiother       Date:  2015-02-17

Review 6.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.

Authors:  Søren M Bentzen; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

7.  Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.

Authors:  Michelle S Bradbury; Dolores Hambardzumyan; Pat B Zanzonico; Jazmin Schwartz; Shangde Cai; Eva M Burnazi; Valerie Longo; Steven M Larson; Eric C Holland
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

8.  Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Authors:  Mette Munk Jensen; Kamille Dumong Erichsen; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Liselotte Højgaard; Maxwell Sehested; Andreas Kjær
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

Review 9.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

10.  Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.

Authors:  Nicolas Graf; Ken Herrmann; Jürgen den Hollander; Falko Fend; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Meyer zum Büschenfelde; Christian Peschel; Markus Schwaiger; Tobias Dechow; Andreas K Buck
Journal:  Mol Imaging Biol       Date:  2008-08-14       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.